SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Jacqueline du Pré

PatientJacqueline Mary du Pré
Date of birth1998-01-26
IdentifiersMRN HR-ML039-SYN; SSN (made up) 000-39-7062
Document date2026-07-13
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three months on ocrelizumab: re-baseline MRI review. [S]

History of Present Illness

Ms. du Pré returns three months after her first ocrelizumab infusion, after a re-baseline MRI five days ago. The cystitis four weeks ago cleared with nitrofurantoin, and the tingling that came back with the fever went within two days of it. She has had no new symptoms. Feeling in her fingers is almost normal except after long practice, and she practices three hours a day. She has started swimming twice a week, which helps the fatigue, and rests after lunch. She played a private recital for friends last week. She takes cholecalciferol daily. [S]

ElementDetail
Disease activityNo relapse since starting ocrelizumab; re-baseline MRI with no new or enhancing lesions
Intercurrent illnessCystitis with a pseudo-relapse four weeks ago, resolved
Hand functionPracticing three hours a day; private recital last week
FatigueBetter with swimming, pacing and an after-lunch rest

Review of Systems

SystemResultFinding
ConstitutionalPositiveMild late-afternoon fatigue; no fever
NeurologicalPositiveFaint tingling in the left fingertips after long practice; no new symptoms
GenitourinaryNegativeNo urinary symptoms since the cystitis
RespiratoryNegativeNo cough
IntegumentaryNegativeNo rash
PsychiatricNegativeMood good; PHQ-9 4; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily for 5 daysOral route2026-06-15 to 2026-06-19completedS
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route2026-03-24 to 2026-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route2026-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route2026-04-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-13Body height173cmS
2026-07-13Body weight64kgS
2026-07-13Body mass index (BMI) [Ratio]21.4kg/m2S
2026-07-13Systolic blood pressure110mm[Hg]S
2026-07-13Diastolic blood pressure70mm[Hg]S
2026-07-13Heart rate70/minS
2026-07-13Respiratory rate14/minS
2026-07-13Body temperature36.6CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-13Hemoglobin [Mass/volume] in Blood13.5g/dL12-15.5 g/dLNormalS
2026-07-13Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-07-13Lymphocytes [#/volume] in Blood by Automated count1.510*3/uL1-4.8 10*3/uLNormalS
2026-07-13Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
2026-07-13CD19 cells [#/volume] in Blood3/uL100-500 /uLLowS
2026-07-13IgG [Mass/volume] in Serum or Plasma990mg/dL700-1600 mg/dLNormalS
2026-07-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientNormalS
2026-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-07-139-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]19sS
2026-07-139-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]20.5sS

Physical Exam

Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 64.0 kg; blood pressure 110/70
NeurologicalVibration slightly reduced in the left fingertips only; joint position, strength, reflexes and gait normal; no Lhermitte's sign. Nine-hole peg test 19.0 seconds right, 20.5 seconds left. EDSS 1.0
PsychiatricBright, warm and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.
Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent infection; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingRe-baseline MRI of the brainThree to six months after starting a disease-modifying therapy, then yearlyUp to dateFive days ago: no new or enlarging T2 lesions, no enhancement
LaboratoryBlood count with lymphocytesEvery three to six months on ocrelizumabCompleted todayHemoglobin 13.5 g/dL, white cells 6.1, lymphocytes 1.5, platelets 240
LaboratoryCD19 B-cell countWhen needed to confirm depletionCompleted today3 per microliter: depleted, as expected
LaboratoryImmunoglobulins (IgG, IgM)At baseline and before each ocrelizumab doseCompleted todayIgG 990 mg/dL
Laboratory25-hydroxyvitamin DAbout three months after starting replacementCompleted today34 ng/mL
LaboratoryHepatitis B surface antibody after vaccinationOne to two months after the last dose, for people on immunosuppressive therapyDeferredMissed: the antibody check due one to two months after the second hepatitis B dose was not ordered. No harm is expected in the meantime, since she has no hepatitis B exposure; corrective action: added to the blood tests before the next ocrelizumab dose, and post-vaccination serology added to the clinic's B-cell therapy checklist
Medication safetyVaccinationComplete series where possibleCompleted todayRecombinant zoster dose 2 today
Medication safetyInfections on anti-CD20 therapyEach reviewCompleted todayOne uncomplicated cystitis, treated; no other infection
ExaminationHand function: nine-hole peg test, both handsAt diagnosis, after a relapse, and at each reviewCompleted today19.0 seconds right, 20.5 seconds left
ExaminationNeurological examination and EDSSEach reviewCompleted todayEDSS 1.0
SurveyMood and anxiety (PHQ-9, GAD-7)At diagnosis and at each reviewCompleted todayPHQ-9 4; item 9 scored 0
Self-managementFatigue: causes and managementEach reviewCompleted todayAerobic exercise (swimming), pacing and rest; no medicine needed

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)

Follow-up: Ocrelizumab 600 mg in three months with blood tests beforehand; preventive visit due; call for fever, urinary symptoms or any new neurological symptom. Next scheduled visit 2026-09-14: periodic adult preventive visit on B-cell therapy. [S]